Sangamo BioSciences | SGMO - Cost Of Sales


Sangamo BioSciences reported 2.42M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Alaunos Therapeutics USD 0 18K Sep/2024
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Bayer EUR 4.5B 194M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Cipla INR 29.1B 1.16B Dec/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.65M 10K Sep/2025
CSL USD 3.87B 2.08B Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Grifols EUR 1.32B 22.75M Sep/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
J&J USD 7.97B 689M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Omeros USD 33.16M 18.52M Jun/2024
Pfizer USD 6.29B 2.12B Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025